A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/06/2011	US20110243893 Markers for determination of patient responsiveness
10/06/2011	US20110243892 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
10/06/2011	US20110243891 Dihydropyrazolopyrimidinone derivative
10/06/2011	US20110243890 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus
10/06/2011	US20110243889 Opioid and opioid-like compounds and uses thereof
10/06/2011	US20110243886 Compounds and pharmaceutical compositions for the treatment of viral infections
10/06/2011	US20110243885 Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function
10/06/2011	US20110243884 Biodegradable polymer - bioactive moiety conjugates
10/06/2011	US20110243883 Polymeric biolubricants for medical use
10/06/2011	US20110243881 Biocompatible polymers, process for their preparation and compositions containing them
10/06/2011	US20110243879 Methods of treating hepatic encephalopathy
10/06/2011	US20110243862 Cosmetic or pharmaceutical composition, in particular intended for care or for makeup
10/06/2011	US20110243856 Permeable Mixtures, Methods and Compositions for the Skin
10/06/2011	US20110243854 Methods and systems for identifying modulators of longevity
10/06/2011	US20110243851 Glucose-peg conjugates for reducing glucose transport into a cell
10/06/2011	US20110243843 Fluorescent silica nanoparticles for detecting lymph node and the identification method of lymph node using thereof
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	US20110240508 Long-term stable pharmaceutical preparation containing the active ingredient glyceryl trinitrate
10/06/2011	US20110240504 Method and apparatus for packaging and dispensing pharmaceuticals
10/06/2011	US20110240022 Aerosol forming device for use in inhalation therapy
10/06/2011	US20110240013 Method of forming an aerosol for inhalation delivery
10/06/2011	DE102011006425A1 Pharmaceutical composition, useful for treating and/or preventing e.g. Parkinson's disease, dementia, neuropathic pain, retinitis pigmentosa, multiple sclerosis and amyotrophic lateral sclerosis, comprises flupirtine and N-acetylcysteine
10/06/2011	DE102010014427A1 Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluorometh yl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances
10/06/2011	DE102010014426A1 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren Using new pan-CDK inhibitors for the treatment of tumors
10/06/2011	DE102010013716A1 Use of amide compounds in combination with epidermal growth factor receptor inhibitor comprising gefitinib and/or erlotinib for the treatment of cancer e.g. lung cancer, colon cancer, bladder cancer, breast cancer and/or ovarian cancer
10/06/2011	DE102010013587A1 N-(Aminoacyl)-Amino-Ester N- (aminoacyl) -amino-ester
10/06/2011	DE102010003494A1 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose Parenteral delivery system that aromatase inhibitors, progestins releases for the treatment of endometriosis
10/06/2011	CA2800507A1 Solid state forms of sitagliptin salts
10/06/2011	CA2799727A1 Polycyclic tetracycline compounds
10/06/2011	CA2795456A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
10/06/2011	CA2795290A1 Use of at least one dialkyl thiosulfonate or thiosulfinate for reducing the number of apicomplexa in an animal
10/06/2011	CA2795257A1 Pharmaceutical formulations for the treatment of overactive bladder
10/06/2011	CA2795253A1 Methods of improving quality of sleep
10/06/2011	CA2795177A1 Method of treating inflammation
10/06/2011	CA2795164A1 Antagonists of mirna-29 expression and their use in the prevention and treatment of aortic aneurysms
10/06/2011	CA2795156A1 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
10/06/2011	CA2795145A1 Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
10/06/2011	CA2795084A1 Polyamine-containing polymers and methods of synthesis and use
10/06/2011	CA2795080A1 Purine compounds
10/06/2011	CA2795064A1 Pyripyropene derivative having acat2 inhibiting activity and stable to metabolizing enzymes
10/06/2011	CA2795062A1 Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
10/06/2011	CA2795054A1 Compounds and pharmaceutical compositions for the treatment of viral infections
10/06/2011	CA2795050A1 Method for preserving alum adjuvants and alum-adjuvanted vaccines
10/06/2011	CA2795038A1 Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
10/06/2011	CA2795023A1 Crystal forms of o-desmethylvenlafaxine fumarate
10/06/2011	CA2795009A1 Aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
10/06/2011	CA2795006A1 Purine compounds used as cb2 agonists
10/06/2011	CA2794996A1 Use of novel pan-cdk inhibitors for treating tumors
10/06/2011	CA2794950A1 Cgrp receptor antagonist
10/06/2011	CA2794930A1 Method for inhibiting hiv replication in mammal and human cells
10/06/2011	CA2794790A1 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis
10/06/2011	CA2794773A1 Trpv1 vanilloid receptor antagonists with a bicyclic portion
10/06/2011	CA2794734A1 Transdermal delivery patch
10/06/2011	CA2794676A1 Cytokine inhibitors
10/06/2011	CA2794671A1 Stereoselective synthesis of phosphorus containing actives
10/06/2011	CA2794669A1 Nucleoside phosphoramidates
10/06/2011	CA2794620A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
10/06/2011	CA2794594A1 Cosmetic and pharmaceutical composition comprising n-acetylglucosamine-6-phosphate
10/06/2011	CA2794570A1 Novel combination and use
10/06/2011	CA2794555A1 Improved treatment of renal cell carcinoma
10/06/2011	CA2794513A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	CA2794443A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
10/06/2011	CA2794392A1 Transcription factor decoys
10/06/2011	CA2794377A1 2-oxo-dihydropyridine non-nucleoside reverse transcriptase inhibitors
10/06/2011	CA2794334A1 Derivatives of 1-amino-2-cyclopropylethylboronic acid
10/06/2011	CA2794315A1 New biomaterial from wharton's jelly umbilical cord
10/06/2011	CA2794308A1 Hypersulfated glucopyranosides
10/06/2011	CA2794280A1 Bioadhesive compositions of local anaesthetics
10/06/2011	CA2793974A1 Methods of treating cancer
10/06/2011	CA2793897A1 Heterocyclic compounds and their uses
10/06/2011	CA2793880A1 Parasiticidal compositions comprising multiple active agents, methods and uses thereof
10/06/2011	CA2793777A1 Formulations of mazindol
10/06/2011	CA2793612A1 Dimethyl sulfoxide (dmso) formulations for treating autism
10/06/2011	CA2793485A1 A fast dissolving pharmaceutical composition
10/06/2011	CA2793409A1 Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull
10/06/2011	CA2793405A1 A fast dissolving pharmaceutical composition
10/06/2011	CA2793313A1 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
10/06/2011	CA2792352A1 Modified release dosage form comprising desvenlafaxine or salts thereof
10/06/2011	CA2792291A1 Sirna therapy for transthyretin (ttr) related ocular amyloidosis
10/06/2011	CA2792269A1 Uses of dgat1 inhibitors
10/06/2011	CA2789307A1 Stable pharmaceutical composition of imatinib
10/06/2011	CA2786657A1 Aryl-cyclohexyl-tetraazabenzo[e]azulenes
10/05/2011	EP2372361A1 Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine
10/05/2011	EP2371959A2 Treatment of neurodegenerative disease through intracranial delivery of siRNA
10/05/2011	EP2371958A1 Novel siRNAs and methods of use thereof
10/05/2011	EP2371957A1 Compositions and their uses directed to hepcidin
10/05/2011	EP2371839A1 Peptidomimetic protease inhibitors
10/05/2011	EP2371834A1 Stabilized immunomodulatory oligonucleotides
10/05/2011	EP2371833A2 10-substituted macrolide antibiotics
10/05/2011	EP2371830A1 Method for producing diamine derivative
10/05/2011	EP2371827A1 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
10/05/2011	EP2371826A1 Novel fused ring compound and use thereof
10/05/2011	EP2371822A1 Heterobicyclic carboxamides as inhibitors for kinases
10/05/2011	EP2371820A1 Optically active cyclic alcohol compound and method for preparing the same
10/05/2011	EP2371819A1 New quinoline derivatives, a method for the production and the use thereof for treating microbacterial infections and a pharmaceutical composition based on said derivatives
10/05/2011	EP2371818A1 Hydroxybenzoate salts of metanicotine compounds
10/05/2011	EP2371816A1 Aminocyclohexenone, their preparation and use as medicament against oxidative stress
10/05/2011	EP2371814A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
10/05/2011	EP2371811A2 Azetidinecarboxylic acid derivative and medicinal use thereof
10/05/2011	EP2371421A1 Ligands of insulin degrading enzyme and their uses

1 ... 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 ... 7860